Business Context and Reporting Period
This Form 8-K is a current report filed by OvaScience, Inc. (not Tempest Therapeutics, Inc.) on April 29, 2015. The filing discloses corporate governance changes, specifically the election of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and compensation arrangements rather than financial performance.
Material Changes
The primary material change is the election of John Sexton, Ph.D., President of New York University, to the Company's Board of Directors as a Class II Director. His term is set to expire at the 2017 annual meeting of stockholders.
Compensation and Governance Details
- Stock Options: Dr. Sexton will receive a non-statutory stock option to purchase 20,650 shares of Common Stock at the next Board meeting in June 2015. The exercise price will equal the closing price on the grant date. These options vest in twelve equal monthly installments.
- Future Grants: Going forward, the policy provides for an annual option grant of 12,000 shares following each annual meeting, vesting over twelve months.
- Cash Compensation: Dr. Sexton will receive an annual fee of $35,000 for his service on the Board.
- Indemnification: An indemnification agreement has been executed to cover certain expenses, including legal fees and judgments, arising from his service as a director.
Investor Verification Checklist
- Verify the exact grant date and exercise price of the 20,650 share option grant scheduled for June 2015.
- Confirm the total number of outstanding shares and the potential dilution impact of the new director grants.
- Review the full text of the Director Compensation Policy to understand the total compensation structure for non-employee directors.
- Check subsequent filings for the actual vesting schedule and any changes to Dr. Sexton's tenure.